Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions

Molecular Pharmacology

Volumn 78, Issue 3, 2010, Pages 466-477

  Zhang, Feng ^a,b,c   Shi, Jing Shan ^b,c   Zhou, Hui ^a   Wilson, Belinda ^a   Hong, Jau Shyong ^a   Gao, Hui Ming ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESVERATROL; ANTIINFLAMMATORY AGENT; DOPAMINE; FLAVONOID; NEUROPROTECTIVE AGENT; PHENOL DERIVATIVE; POLYPHENOL; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL MEMBRANE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; GLIA CELL; MESENCEPHALON; MICROGLIA; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; ANIMAL EMBRYO; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CYTOLOGY; DRUG EFFECTS; FEMALE; FISCHER 344 RAT; GLIA; METABOLISM; NERVE CELL; PARKINSON DISEASE; PHYSIOLOGY; PREGNANCY; SUBSTANTIA NIGRA; TOXICITY AND INTOXICATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DOPAMINE; EMBRYO, MAMMALIAN; FEMALE; FLAVONOIDS; LIPOPOLYSACCHARIDES; MESENCEPHALON; MICE; MICE, INBRED C57BL; MICROGLIA; MITOGEN-ACTIVATED PROTEIN KINASES; NADPH OXIDASE; NERVE DEGENERATION; NEUROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; PARKINSON DISEASE; PHENOLS; POLYPHENOLS; PREGNANCY; RATS; RATS, INBRED F344; REACTIVE OXYGEN SPECIES; STILBENES; SUBSTANTIA NIGRA;

EID: 77956242222     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.064535     Document Type: Article

References (38)

1. Akira S, Takeda K, and Kaisho T (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2:675-680. (Pubitemid 32747155)
2. Bardwell L (2006) Mechanisms of MAPK signalling specificity. Biochem Soc Trans 34:837-841.
3. Bhat NR, Zhang P, Lee JC, and Hogan EL (1998) Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures. J Neurosci 18:1633-1641.
4. Bi XL, Yang JY, Dong YX, Wang JM, Cui YH, Ikeshima T, Zhao YQ, and Wu CF (2005) Resveratrol inhibits nitric oxide and TNF-alpha production by lipopolysaccharide-activated microglia. Int Immunopharmacol 5:185-193.
5. Candelario-Jalil E, de Oliveira AC, Gräf S, Bhatia HS, Hüll M, Muñoz E, and Fiebich BL (2007) Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation 4:25.
6. Chow SE, Hshu YC, Wang JS, and Chen JK (2007) Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages. J Appl Physiol 102:1520-1527.
7. Dang PM, Stensballe A, Boussetta T, Raad H, Dewas C, Kroviarski Y, Hayem G, Jensen ON, Gougerot-Pocidalo MA, and El-Benna J (2006) A specific p47phox-serine phosphorylated by convergent MAPKs mediates neutrophil NADPH oxidase priming at inflammatory sites. J Clin Invest 116:2033-2043.
8. Das S and Das DK (2007) Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets 6:168-173.
9. Gao HM and Hong JS (2008) Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 29:357-365.
10. Gao HM, Hong JS, Zhang W, and Liu B (2002a) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22:782-790.
11. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, and Liu B (2002b) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 81:1285-1297.
12. Gao HM, Liu B, Zhang W, and Hong JS (2003a) Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J 17:1954-1956.
13. Gao HM, Liu B, Zhang W, and Hong JS (2003b) Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 24:395-401.
14. Greenamyre JT, MacKenzie G, Peng TI, and Stephans SE (1999) Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp 66:85-97.
15. Groemping Y and Rittinger K (2005) Activation and assembly of the NADPH oxidase: a structural perspective. Biochem J 386:401-416.
16. Hirsch E, Graybiel AM, and Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334:345-348.
17. Hirsch EC and Hunot S (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8:382-397.
18. Jang S, Kelley KW, and Johnson RW (2008) Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci USA 105:7534-7539.
19. Jenner P and Olanow CW (1998) Understanding cell death in Parkinson's disease. Ann Neurol 44 (3 Suppl 1):S72-S84. (Pubitemid 28423832)
20. Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK, and Shi X (2003) Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 309:1017-1026.
21. Liu B, Du L, and Hong JS (2000) Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 293:607-617.
22. Markus MA and Morris BJ (2008) Resveratrol in prevention and treatment of common clinical conditions of aging. Clin Interv Aging 3:331-339.
23. McGuire SO, Ling ZD, Lipton JW, Sortwell CE, Collier TJ, and Carvey PM (2001) Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp Neurol 169:219-230.
24. Meng XL, Yang JY, Chen GL, Wang LH, Zhang LJ, Wang S, Li J, and Wu CF (2008) Effects of resveratrol and its derivatives on lipopolysaccharide-induced microglial activation and their structure-activity relationships. Chem Biol Interact 174:51-59.
25. Miller RL, James-Kracke M, Sun GY, and Sun AY (2009) Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 34:55-65.
26. Nagatsu T, Mogi M, Ichinose H, and Togari A (2000) Cytokines in Parkinson's disease. J Neural Transm Suppl 58:143-151.
27. Nagatsu T and Sawada M (2006) Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. Cell Mol Neurobiol 26:781-802.
28. Park DW, Baek K, Kim JR, Lee JJ, Ryu SH, Chin BR, and Baek SH (2009) Resveratrol inhibits foam cell formation via NADPH oxidase 1- mediated reactive oxygen species and monocyte chemotactic protein-1. Exp Mol Med 41:171-179.
29. Pawate S, Shen Q, Fan F, and Bhat NR (2004) Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma. J Neurosci Res 77:540-551.
30. Qian L, Tan KS, Wei SJ, Wu HM, Xu Z, Wilson B, Lu RB, Hong JS, and Flood PM (2007) Microglia-mediated neurotoxicity is inhibited by morphine through an opioid receptor-independent reduction of NADPH oxidase activity. J Immunol 179:1198-1209.
31. Qian L, Wei SJ, Zhang D, Hu X, Xu Z, Wilson B, El-Benna J, Hong JS, and Flood PM (2008) Potent anti-inflammatory and neuroprotective effects of TGF-beta1 are mediated through the inhibition of ERK and p47phox-Ser345 phosphorylation and translocation in microglia. J Immunol 181:660-668.
32. Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B, Liu B, and Hong JS (2004) NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. The Journal of biological chemistry 279:1415-1421.
33. Ramanan S, Kooshki M, Zhao W, Hsu FC, and Robbins ME (2008) PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways. Free Radic Biol Med 45:1695-1704.
34. Saiko P, Szakmary A, Jaeger W, and Szekeres T (2008) Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 658:68-94.
35. Spanier G, Xu H, Xia N, Tobias S, Deng S, Wojnowski L, Forstermann U, and Li H (2009) Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol 60 (Suppl 4):111-116.
36. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, and O'Callaghan JP (2002) Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J 16:1474-1476.
37. Tan AS and Berridge MV (2000) Superoxide produced by activated neutrophils efficiently reduces the tetrazolium salt, WST-1 to produce a soluble formazan: a simple colorimetric assay for measuring respiratory burst activation and for screening anti-inflammatory agents. J Immunol Methods 238:59-68.
38. Zhang W, Shin EJ, Wang T, Lee PH, Pang H, Wie MB, Kim WK, Kim SJ, Huang WH, Wang Y, et al. (2006) 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro. FASEB J 20:2496-2511.